Alchemia Limited is a biotechnology company. The Company is engaged in the sale of its around the world intellectual property rights to Fondaparinum sodium, a generic anti-coagulant drug to Dr Reddy's Laboratories; closure of clinical trial activities, and review of new opportunities. The Company's segments include Fondaparinux and HyACT. The Company is engaged in the commercialization and improvements of its generic Fondaparinux product. The Company's HyACT is a platform technology that targets cancer drugs directly to tumors, designed to increase effectiveness against tumors without increasing toxicity. Its lead product candidate, HA-Irinotecan is used in the treatment of metastatic colorectal cancer (mCRC) and is in Phase III clinical trials. Its subsidiary, Alchemia Oncology Inc. is engaged in commercializing its HyACT and VAST platforms, including HA-Irinotecan. The Company's Audeo Oncology, Inc is engaged in the development and commercialization of the HyACT platform.